Stock ELTX ELICIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 23:00:00 22/05/2024 BST 		5-day change 1st Jan Change
8.85 USD -0.11% Intraday chart for Elicio Therapeutics, Inc. -11.94% +6.12%
05-23 Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting CI
04-05 Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 80.11 85.96 - -
Enterprise Value (EV) 1 80.11 85.96 85.96 85.96
P/E ratio - - - -
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / FCF - - - -
FCF Yield - - - -
Price to Book - - - -
Nbr of stocks (in thousands) 9,606 10,221 - -
Reference price 2 8.340 8.410 8.410 8.410
Announcement Date 29/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 - -35.74 -44.14 -52.7 -62.29
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -28.21 - - - -
Net margin - - - - -
EPS -1.620 - - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 29/03/23 29/03/24 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - -
EBITDA - - - - - -
EBIT 1 -10.77 -9.392 -10.24 -10.75 -11.29 -11.86
Operating Margin - - - - - -
Earnings before Tax (EBT) - - - - - -
Net income - - - - - -
Net margin - - - - - -
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 09/11/23 29/03/24 15/05/24 - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - 0.07 - - -
Capex / Sales - - - - -
Announcement Date 29/03/23 29/03/24 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.41 USD
Average target price
10 USD
Spread / Average Target
+18.91%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ELICIO THERAPEUTICS, INC. Stock Elicio Therapeutics, Inc.
+6.12% 85.96M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.04% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ELTX Stock
  4. Financials Elicio Therapeutics, Inc.